Our cells can steal our genetic code to turn on genes that were meant to turn off
Scientists can see this in their lab and think it is not so bad.
However, a key part of science is to figure out the cause of the problem. And if we could reverse the problem by cutting out a specific gene, that would be great.
So scientists have done this in mice, by cutting out a gene that is involved in the activation of a type of cell that causes Alzheimer’s.
This work is not yet fully understood, but it does suggest that there is something wrong with the activation of the protein on this gene.
In this process, there is no disruption of normal cell division, so it could be a new pathway to create Alzheimer’s in humans.
Some scientists think this may be a good thing. It is unlikely that Alzheimer’s will become a widespread disease if the cells can be repaired.
But others are concerned that it could mean that more people will get Alzheimer’s.
That would be a big problem.
Alzheimer’s affects 1 in 5 people in the UK and a quarter of a million people in the US.
But research in the last decade has been encouraging.
For example, the world’s first treatment for Alzheimer’s – amyloid beta 42 – was tested on patients in the UK in the late 1990s.
But the results were not so good.
This caused a huge uproar.
Many people were worried that the drug would make people more likely to get Alzheimer’s.
A different drug, A-11, was developed in the US, but was found to be far less effective.
What are Alzheimer’s genes?
Alzheimer’s disease is a progressive disease which gradually destroys brain cells.
A change in the balance of brain cells called an imbalance is one of the causes of the disease.
The changes occur because of a mutation in the genes that make proteins that help to keep the brain cells healthy.
The proteins they make are called amyloid proteins.
One of the ways this happens is that some amyloid proteins are broken down into shorter versions.
These can become plaques, which block the brain’s connections between brain cells.
These plaques are thought to play a role in the development of Alzheimer’s.
What are Alzheimer’s proteins?
A-11 was the first drug to be developed to target amyloid.
A-11 works by binding to amyloid proteins and blocking them from binding to their targets.
This helps the brain cells to work more effectively.
This treatment, which was approved by the US Food and Drug Administration (FDA) in 2002, was followed by trials in people with other forms of dementia.
This research showed that amyloid treatment improved cognitive function in people with other forms of dementia.
However, it had not been possible to find a way to target amyloid without making people more likely to get Alzheimer’s.
That’s where NRP came in.
It has identified five “Alzheimer’s risk genes” that are associated with an increased risk of developing Alzheimer’s.